Rapid Micro Biosystems Inc RPID.OQ RPID.O is expected to show a rise in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2025
The Lexington Massachusetts-based company is expected to report a 38.1% increase in revenue to $11.35 million from $8.22 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Rapid Micro Biosystems Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 100.5% above its last closing price of $3.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.24 | -0.24 | -0.26 | Missed | -6.1 |
Jun. 30 2025 | -0.24 | -0.25 | -0.27 | Missed | -6.6 |
Mar. 31 2025 | -0.27 | -0.27 | -0.26 | Beat | 3.7 |
Dec. 31 2024 | -0.23 | -0.23 | -0.22 | Beat | 4.3 |
Sep. 30 2024 | -0.25 | -0.26 | Missed | -2 | |
Jun. 30 2024 | -0.28 | -0.28 | -0.29 | Missed | -4.8 |
Mar. 31 2024 | -0.29 | -0.29 | -0.31 | Missed | -6.9 |
Dec. 31 2023 | -0.30 | -0.30 | -0.26 | Beat | 13.3 |
This summary was machine generated February 24 at 14:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)